Print   



23 January 2009

NextGen Group PLC

Extraordinary General Meeting

Share Issue Authority

The Board of NextGen Group PLC ('NextGen' or the 'Company') announces that an Extraordinary General Meeting of the Company has been be convened for 29 January 2009 at 10.00 a.m. at the offices of Seymour Pierce Limited at 20 Old Bailey, London EC4M 7EN.

A circular containing the Notice of Extraordinary Meeting has been posted to Shareholders, and is available on the Company's website: www.nextgensciences.com

Introduction 

The Board announced on 13 October 2008 and 27 November 2008 that the Company had raised gross funds of £315,000 and £639,000, respectively, through placings of new Ordinary Shares (the 'Placings'). The Placings utilised the existing share issue authorities of the Directors. 

Accordingly, the Board is seeking renewal of their general authorities to issue Ordinary Shares and/or other securities of the Company, such general authority being last granted to them at the Annual General Meeting of the Company held on 5 August 2008. 

In addition, the current authorised share capital of the Company is £3,000,000 divided into 3,000,000,000 Ordinary Shares of £0.001 each. The number of Ordinary Shares issued pursuant to the Placings together with the existing committed share capital requirements of the Company (including existing options and warrants) mean that the authorised share capital of the Company must be increased. It is, therefore, proposed that the authorised share capital be increased from £3,000,000 to £4,500,000 by the creation of 1,500,000,000 Ordinary Shares.

Extraordinary General Meeting

The grant of general authorities to issue Ordinary Shares and/or other securities of the Company and to an increase in the authorised share capital of the Company requires Shareholder approval.

Accordingly, an Extraordinary General Meeting of the Company has been convened for the purpose of increasing the share capital of the Company, granting the Directors authority to allot Ordinary Shares and to disapply pre-emption rights in connection with such allotments for which the requisite approval of the Shareholders is required. 

Enquiries:

NextGen Group
Dr Michael Pisano, CEO	+1 734 973 7914
College Hill
Lorna Cuddon/Adrian Duffield	+44 20 7457 2020
nextgen@collegehill.com
Seymour Pierce (Nomad for NextGen)
Jonathan Wright/Nicola Marrin	+44 20 7107 8000

Notes to Editors

NextGen Group PLC www.nextgensciences.com

NextGen Group PLC is a provider of biomarker services for pharmaceutical and biotech companies globally. A biomarker is a substance (e.g. a protein) used as an indicator of a biologic state. A biomarker can be measured from a clinical sample, such as blood or urine, and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.  The Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients. 

NextGen's range of services, which include biomarker testing, discovery and assay development, are employed by its customers as a key part of the biomarker-based drug and diagnostic development process. 

---

ENDNOEBTMRTMMITBTL